Dihydroartemisinin restrains angiogenesis through the TNF-α pathway to enhance the efficacy of anti-PD-1 immunotherapy in breast cancer
Biochemical and Biophysical Research Communications · 2025
DOI: 10.1016/j.bbrc.2025.152171 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2025. Verfasst von Meng Zou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medicine, Hubei University of Chinese Medicine, Wuhan, 430065, China; Hubei Shizhen Laboratory, Wuhan, 430065, China; Center of T…. Hauptthemen laut MEDLINE: Artemisinins, Breast Neoplasms, Neovascularization, Pathologic, Tumor Necrosis Factor-alpha. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Natural Science Foundation of Hubei Province, Double first-class construction project of Hubei Univercity of Chinese Medcine, Hubei Province Natural Science Foundation.
Abstract (Originalsprache)
Tumor vascular abnormality promotes the formation of immunosuppressive microenvironment, thus limiting the efficacy of tumor immunotherapy and promoting tumor development. Dihydroartemisinin (DHA) has shown potential as an anti-tumor agent. The potential role of its anti-angiogenic effect has not yet been discovered. This research investigates whether DHA inhibits tumor-induced angiogenesis, promotes immunotherapy and explored the underlying mechanism. The promoting effect of 4T-1 cell-conditioned media (CM) on SVEC4-10 activity and tube formation can be reversed by DHA-treated with CM. Consistently, following DHA administration in a breast cancer mouse model, the number of transplanted tumor vessels was markedly reduced and perivascular cells increased. Subsequently, in vivo administration of DHA evidently promoted inhibitory effect of anti-PD-1 in tumor and reversed the infiltration of T cells and the phenotypes of macrophages. Network pharmacology and RNA-seq analysis revealed that DHA inhibit tumor growth by angiogenesis through the TNF-α pathway. Besides, TNF-α cytokine replenishment experiment and the expression of key molecules involved signaling pathway confirmed the above mechanism. In conclusion, DHA alleviates tumor cell-induced abnormal blood vessels through TNF-α pathway, which contributes to the anti-PD-1 efficacy of tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Medicine, Hubei University of Chinese Medicine, Wuhan, 430065, China; Hubei Shizhen Laboratory, Wuhan, 430065, China; Center of Traditional Chinese Medicine Modernization for Liver Diseases, Hubei Un…
- Department of Basic Medicine, Hubei University of Chinese Medicine, Wuhan, 430065, China; Hubei Shizhen Laboratory, Wuhan, 430065, China.
Förderung
- Natural Science Foundation of Hubei Province
- Double first-class construction project of Hubei Univercity of Chinese Medcine
- Hubei Province Natural Science Foundation
- Defense Health Agency
- Hubei University of Medicine
Zitieren
APA
Zou, M., Gong, Y., Zeng, J., Zhang, X., Guo, X., Hua, J., Chen, Z., Lin, L., & Wu, F. (2025). Dihydroartemisinin restrains angiogenesis through the TNF-α pathway to enhance the efficacy of anti-PD-1 immunotherapy in breast cancer. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2025.152171
Vancouver
Zou M, Gong Y, Zeng J, Zhang X, Guo X, Hua J, et al. Dihydroartemisinin restrains angiogenesis through the TNF-α pathway to enhance the efficacy of anti-PD-1 immunotherapy in breast cancer. Biochemical and Biophysical Research Communications. 2025. doi:10.1016/j.bbrc.2025.152171
BibTeX
@article{Zou2025,
author = {Zou, Meng and Gong, Yu and Zeng, Jiawei and Zhang, Xiyu and Guo, Xiaohong and Hua, Jianghuan and Chen, Zhuobin and Lin, Li and Wu, Fenghua},
title = {Dihydroartemisinin restrains angiogenesis through the TNF-α pathway to enhance the efficacy of anti-PD-1 immunotherapy in breast cancer},
journal = {Biochemical and Biophysical Research Communications},
year = {2025},
doi = {10.1016/j.bbrc.2025.152171}
}
EUVIMED